Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1746541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Xiaorong Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescent…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B Surface Antigens, Antiviral Agents, Hepatitis B virus. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Serum hepatitis B virus (HBV) pregenomic RNA (pgRNA) predicts antiviral response in adults with chronic hepatitis B (CHB); however, its prognostic performance against conventional biomarkers in children remains underexplored. This study aimed to characterize the kinetics of pgRNA and hepatitis B surface antigen (HBsAg) and evaluate their predictive value for treatment outcomes in children with CHB.
Methods
Sixty-five hepatitis B e antigen (HBeAg)-positive children with CHB who received ≥ 96 weeks of nucleos(t)ide analogue (NA) therapy were included. Serum viral biomarkers were measured at baseline, weeks 12, 48, and 96. Treatment outcomes were HBeAg seroconversion and HBsAg loss (Defined as HBsAg <100 IU/mL or seroclearance).
Results
Patients initiating treatment before age 7 years had a significantly higher cumulative incidence of HBeAg seroconversion (73.5% vs. 48.4%) and HBsAg loss (50.0% vs. 9.7%) compared to older children ( p < 0.05). Week 12 HBV pgRNA decline was an independent predictor of HBeAg seroconversion (area under the curve [AUC] = 0.793, 95% confidence interval [CI]: 0.686–0.900), outperforming HBV DNA and HBsAg kinetics. For predicting HBsAg loss, the week 12 HBsAg decline was an independent predictor (AUC = 0.762, 95% CI: 0.632–0.893), and its integration with patient age further improved predictive accuracy (AUC = 0.879, 95% CI: 0.796–0.962).
Conclusions
Early pgRNA kinetics more accurately predict HBeAg seroconversion, whereas HBsAg dynamics forecast HBsAg loss more effectively, particularly when combined with patient age. This complementary monitoring strategy provides a clinically applicable tool for optimizing personalized management in children with CHB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child…
- Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, Chongq…
Zitieren
APA
Peng, X., Chang, Y., Wu, J., Zhu, J., Hu, P., Ren, H., Xu, H., Zhao, R., & Qin, T. (2026). Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1746541
Vancouver
Peng X, Chang Y, Wu J, Zhu J, Hu P, Ren H, et al. Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1746541
BibTeX
@article{Peng2026,
author = {Peng, Xiaorong and Chang, Yunan and Wu, Jiaying and Zhu, Jing and Hu, Peng and Ren, Hong and Xu, Hongmei and Zhao, Ruiqiu and Qin, Tao},
title = {Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1746541}
}
EUVIMED